Ocular Therapeutix

SEC subpoenas Ocular Therapeutix over pain relief implant
SEC subpoenas Ocular Therapeutix over pain relief implant
Drug Delivery Business News
SEC
Ocular Therapeutix
pain relief implant
Dextenza
post-surgical pain
Flag link:
Ocular Therapeutix Hit by Subpoena, SEC Seeks Eye Pain Drug Documents
Ocular Therapeutix Hit by Subpoena, SEC Seeks Eye Pain Drug Documents
Xconomy
Ocular Therapeutix
SEC
eye pain
Dextenza
Flag link:
Ocular’s new CEO to ‘aggressively’ seek partnerships
Ocular’s new CEO to ‘aggressively’ seek partnerships
Drug Delivery Business News
Ocular Therapeutix
Antony Mattessich
Flag link:
Ocular Therapeutix slashes workforce following FDA rejection
Ocular Therapeutix slashes workforce following FDA rejection
Drug Delivery Business News
Ocular Therapeutix
layoffs
FDA
devices
Dextenza
Flag link:
FDA rejects Ocular Therapeutix eye drug, citing manufacturing issues
FDA rejects Ocular Therapeutix eye drug, citing manufacturing issues
Stat
FDA
Ocular Therapeutix
Dextenza
Flag link:
Ocular touts patient experience data for Dextenza implant
Ocular touts patient experience data for Dextenza implant
Drug Delivery Business News
devices
Ocular Therapeutix
eye health
Dextenza
post-surgical pain
Flag link:
Ocular Therapeutix touts data from phase III trial of Dextenza
Ocular Therapeutix touts data from phase III trial of Dextenza
Mass Device
Ocular Therapeutix
Dextenza
devices
post-surgical ocular inflammation and pain
eye health
Flag link:
Biotechs line up to tap growing ophthalmics market
Biotechs line up to tap growing ophthalmics market
BioPharma Dive
Ophthalmic Drugs Market
Ocular Therapeutix
Eylea
Restasis
Lucentis
Regeneron
Roche
Allergan
Flag link:
Regeneron picks a new delivery tech in effort to upgrade flagship blockbuster Eylea
Regeneron picks a new delivery tech in effort to upgrade flagship blockbuster Eylea
Endpoints
Regeneron
Eylea
Ocular Therapeutix
drug delivery
Flag link:
4 Biotech Stocks You Should Be Watching Right Now
4 Biotech Stocks You Should Be Watching Right Now
TheStreet.com
Five Prime
Inovio
Medivation
Ocular Therapeutix
Flag link:
The Top 4 Biopharma Movers of the Past Week
The Top 4 Biopharma Movers of the Past Week
24/7 Wall St
Ocular Therapeutix
Regulus
Zafgen
Aerie Pharma
Flag link:
8 BioPharma Movers That Cannot Be Ignored
8 BioPharma Movers That Cannot Be Ignored
24/7 Wall St
AbbVie
Gilead Sciences
Endo International
Synta Pharmaceuticals
Valeant Pharmaceuticals
Relypsa
Repros Therapeutics
Ocular Therapeutix
Flag link:
Ocular Therapeutix plunges as eye treatment blurs the line in PhIII
Ocular Therapeutix plunges as eye treatment blurs the line in PhIII
Fierce Biotech
Ocular Therapeutix
OTX-DP
Flag link:
3 Biotech Stocks With Upcoming Data That Could Be Huge
3 Biotech Stocks With Upcoming Data That Could Be Huge
24/7 Wall St
Aerie Pharma
Ocular Therapeutix
Xoma
gevokizumab
Rhopressa
OTX-TP
Flag link:
IPO Preview: Ocular Therapeutix
IPO Preview: Ocular Therapeutix
Seeking Alpha
IPOs
Ocular Therapeutix
Flag link:
Baxter buys stake in Ocular Therapeutix
Baxter buys stake in Ocular Therapeutix
Mass Device
Baxter International
Ocular Therapeutix
devices
M&A
Flag link:
Glaucoma: Ocular Therapeutix launches Phase II trial of tear duct plug
Glaucoma: Ocular Therapeutix launches Phase II trial of tear duct plug
glaucoma
Ocular Therapeutix
clinical trials
Flag link:
Ocular Therapeutix drums up $6 million
Ocular Therapeutix drums up $6 million
Ocular Therapeutix
Flag link: